Table 3 Characteristics of studies and body composition in rheumatoid arthritis patients under bDMARDs treatment
References | Study design | Total N | No of patients/intervation | No of patients/control | Duration | Age (mean) | BC assessment | Total Weight kg before/after (SD) | BMI before/after (SD)(CI)*** | FM kg /or %* before/after (SD) | FFM kg before/after (SD) (CI)*** |
|---|---|---|---|---|---|---|---|---|---|---|---|
Marcora et al. [19] | Prospective Rand Cohort | 26 | 12 TNFi | 14 RA MTX | 6 | 52 | DXA | 76.4 (14.4) 77.5 (16.1) | 28.0 (7) na | 31.7 (8.2) 32.3 (8.5) | 43.8 (10) 44.3 (10.9) |
Serelis et al. [11] | Prospective Cohort | 19 | 19 TNFi | no | 12 | 54 | DXA | 69.5 (12.6) 69.8 (12.6) | 26.1 (4.98) 26.3 (4.12) | 28.4 (10.1) 28.5 (10.2) | 39.7 (7.4) 39.8 (7.3) |
Engvall et al [12]. | Prospective Rand Cohort | 40 | 18 TNFi | 22 RA csDMARD | 21 | 57.7 | DXA | na | 24.7 (3.7) Δ + 0.89 | 24.4 (7.5) Δ + 37.7** | 45.9 (9.4) Δ + 570 |
Kopec-Medrek et al. [15] | Prospective Cohort | 32 | 16 TNFi | 16 healthy | 14 | na | DXA | 69.2 (3.64) 70.8 (3.44) | 26.0 (1.29) 26.6 (1.23) | 26.7 (2.9) 28.0 (2.6)** | 40.2 (1.46) 40.5 (1.07) |
Toussirot et al. [16] | Prospective Cohort | 20 | 8 TNFi | 12 AS TNFi | 24 | 60.5 | DXA | 66.4 (4.4) 67.5 (4.3) | 23.4 (0.73) 24.1 (0.8)** | 18.6 (1.8) 20.0 (1.8) | 46.0 (4.2) 45.8 (4.3) |
Tournadre et al. [23] | Prospective Cohort | 42 | 21 TCZ | 21 Met. Syndrome | 12 | 57.8 | DXA | 61.8 (19.3) 63.7 (16.1)** | 23.6 (6.7) 24.8 (5.9)** | 19.5 (1.2) 19.5 (9.5) | 42.1 (1.1) 43.2 (1.1)** |
Van den Oever et al. [20] | Prospective Cohort | 56 | 28 TNFi | 28 OA | 6 | 54 | DXA | na | 26.2 (4.0) 25.7 (3.5) | 37% (11)* 37% (11)* | 46.1 (7.6) 46.7 (7.7) |
Toussirot et al. [21] | Prospective Cohort | 107 | 107 TCZ | No | 12 | 56.6 | DXA | 70.3 (15.1) 72 (15.3)** | 26.4 (5.5) 27.2 (5.8) | 27.7 (12.1) 28.1 (1.1) | 40.7 (8.4) 42.1 (8.9)** |
Hasegawa et al. [30] | Prospective Cohort | 48 | 34 TNFi, 9ABT, 5TCZ | No | 12 | 64.2 | DXA | 54.6 (12.4) 55.8 (13.6)** | na | na | 5.1 (0.5)# 5.3 (0.7)** |
Vial et al. [28] | Prospective Cohort | 83 | 47 TNF | 18 csDMARD 10 RTX, 6 ABT, 2 TCZ | 12 | 58.5 | DXA | na | 26.7 (6.4) 27.0 (6.5) | 25.3 (12.2) 25.4 (11.5) | 49.6 (10.8) 50.7 (11.3)** |
Metsios et al. [24] | Prospective Cohort | 32 | 20 TNFi | 12 healthy | 3 | 60 | Bioimp | 79.4 (15.6) 78.8 (16.6) | 28.3 (3.7) 28.1 (4.1) | 38.8% (7.5)* 36.0% (7.4)* | 50.9 (12.7) 51.1 (12.5) |
Ferraz-Amaro et al. [13] | Prospective Cohort | 120 | 16 TNFi | 34 AR csDMARD 70 healthy | 12 | 53.6 | Bioimp | 72.0 (14.0) 73.9 (13.7)** | 26.9 (3.88) 28.0 (4.57)** | 19.8 (7) 22.0 (9.7) | 53.7 (48.7–62.3)*** 50.5 (44.2–58.5) |
Chin-Yen Chen et al. [25] | Prospective Cohort | 30 | 20 TNFi | 10 RA csDMARD | 12 | 54.7 | Bioimp | 55.8 (10.6) 57.7 (11.3)** | 22.0 (3.2) 22.8 (3.6)** | 29.5% (5.8)* 30.7% (6.0)* | na |
Ramos et al. [18] | Transversal | 123 | 21 TNFi | 23 RA csDMARD 79 healthy | 48 | 54.8 | Skin fold | na | 28.1 (25–31)*** na | na | na |
Brown et al. [14] | Prospective Cohort | 168 | 168 TNFi | no | 24 | 63.8 | BMI | 75.3 (17.59) Δ + 1.80** | 26.5 (5.19) na | na | na |
Sfriso et al. [17] | Prospective Cohort | 131 | 91 TNFi | 40 RA MTX | 24 | 59.9 | BMI | 62.2 Δ + 2.4** | 23.25 na | na | na |
Chapman et al. [26] | Prospective Cohort | 19 | 19 TCZ | no | 6 | 49.6 | BMI | na | 25.5 (21–32)*** 26.0 (21–32)** | na | na |
Choi et al. [22] | Prospective Cohort | 131 | 87 TCZ | 44 RA MTX | 6 | 52.8 | BMI | 53.4 (8.6) 4.3 (8.4)** | 22.6 na | na | na |